TCR-T cell therapy for solid tumors with TP53 R248Q mutation
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized cell therapy called TP53 R248Q TCR-T for people with advanced solid tumors that have a specific genetic change (TP53 R248Q mutation). The treatment uses your own immune cells modified to attack cancer cells, and may be an option if standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed solid tumor (lung, colon, pancreatic, or other type) that has grown after standard treatment.
- Your tumor must have a specific genetic mutation called TP53 R248Q, found through DNA or RNA testing.
- You must be in good overall health (able to care for yourself, ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You must provide a recent tumor sample (within the past 2 years) or be willing to have a biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, DCTY1102, for people with advanced solid tumors like pancreatic, colorectal, or lung cancer who have tried other treatments. It uses your own immune cells that are modified to target a specific genetic change in your tumor.
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.